Ataxia Telangiectasia Clinical Trial
Official title:
Eye-tacking Method as a Diagnostic Tool for Assessment of Oculomotor Parameters (Gaze-holding Score, Scan Path, Visually Guided Saccades Etc) in Pediatric Patients With Ataxia Telangiectasia
NCT number | NCT05471310 |
Other study ID # | LB_03/17/22 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 15, 2021 |
Est. completion date | June 30, 2022 |
Verified date | July 2022 |
Source | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Ataxia-telangiectasia (A-T) is a multisystem auto-somal recessive disorder linked to the A-T mutated gene (ATM) on chromosome 11q22-23, and characterized by progressive neural degeneration, immunodeficiency, and progressive ocular motor dysfunction. In previous studies, the quantitative description of the ocular motor deficits from clinical examination was limited to various defects in saccade and gaze control, dysmetric saccades, impairments of smooth pursuit, gaze holding, convergence, vestibular and optokinetic nystagmus slow phases, and cancellation of the vestibulo-ocular reflex. The aim of our research is to add existing findings with quantitative description of oculomotor patterns in A-T patients using videooculography (VOG).
Status | Completed |
Enrollment | 5 |
Est. completion date | June 30, 2022 |
Est. primary completion date | March 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 8 Years to 17 Years |
Eligibility | Inclusion Criteria: - confirmed diagnosis of ataxia telangiectasia, - informed consent, - stay at the Clinical Research Rehabilitation Center "Russkoe Pole" for 14 days. Exclusion Criteria: - epilepsy, - poor visual acuity, inability to percept from a computer monitor, - inability to hold head and posture satisfactory to perform the tasks, - difficulty to obtain adequate recordings due to corrective lenses, - visual field defects. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Clinical Rehabilitation Research Center "Russkoe pole" | Chéjov |
Lead Sponsor | Collaborator |
---|---|
Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gaze holding task | A fixation task in which the subject will require to look at a target-a green circle (diameter ~1) sequentially presented at eccentric (15 rightward and leftward, 8 upward and downward) positions, each eccentric position being sustained for 20 s. Gaze-holding score will be assessed for each circle by approximating the gaze position coordinates by the least squares method to obtain the best correspondence using the fit function. The areas of the obtained ellipses, reflecting the spread of gaze position coordinates, will be determined for each of the four circle positions in each subject. Areas will be expressed in square visual degrees (sq. deg.) | baseline, during the intervention-rehabilitation course (once) | |
Primary | Visual search task | Ten black circles (diameter ~1) will be presented on the monitor distributed pseudorandomly over the screen. Subjects will be instructed to count silently the number of points and give a verbal response. Study parameters: the performance time, the number of fixations, their durations, the total length of the scanning trajectory, and the saccade amplitude. | baseline, during the intervention-rehabilitation course (once) | |
Primary | Visually guided saccade task | The subject will be required to follow a target jumping their gaze from one corner of the square to the next as quickly as possible as soon as a circle appeared; saccades will be required in order to do this (An image of a square with side length 10° will be presented on the monitor and a red circle (diameter ~1°) appeared in the corners sequentially in the clockwise direction.) Study parameters: the total number of saccades completed, the proportions of relatively accurate (A in the range 8.5-11.5°), hypometric (short, A < 8.5°), and hypermetric (long, A > 11.5°), and corrective saccades (occurring only after dysmetric saccades, 1.5° < A < 5°); | baseline, during the intervention-rehabilitation course (once) | |
Secondary | Scale for the assessment and rating of ataxia | A clinical scale that is based on a semi-quantitative assessment of cerebellar ataxia on an impairment level. | baseline, during the intervention-rehabilitation course (once) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02345135 -
Susceptibility to Infections in Ataxia Telangiectasia
|
N/A | |
Active, not recruiting |
NCT04991701 -
A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia
|
||
Active, not recruiting |
NCT05531890 -
Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05692596 -
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
|
||
Completed |
NCT05252819 -
Whole Body MRI for Cancer Surveillance in A-T
|
||
Recruiting |
NCT03357978 -
Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia
|
N/A | |
Withdrawn |
NCT02309632 -
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
|
N/A | |
Not yet recruiting |
NCT06324877 -
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside
|
N/A | |
Not yet recruiting |
NCT01075438 -
Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients
|
N/A | |
Completed |
NCT03962114 -
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia
|
Phase 2 | |
Completed |
NCT04513002 -
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis
|
Phase 2 | |
Active, not recruiting |
NCT04870866 -
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia
|
Phase 2 | |
Recruiting |
NCT06193200 -
To Evaluate the Effects of EryDex in Patients With A-T
|
Phase 3 | |
Recruiting |
NCT03563053 -
Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study
|
Phase 3 | |
Recruiting |
NCT05692622 -
Home-based Complex Intervention for Children With Ataxia Telangiectasia
|
N/A | |
Recruiting |
NCT04037189 -
Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia
|
||
Not yet recruiting |
NCT04887311 -
MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia
|
Phase 2 | |
Active, not recruiting |
NCT00951886 -
The Validity of Forced Expiratory Maneuvers in Ataxia Telangiectasia Studied Longitudinally
|
N/A | |
Recruiting |
NCT03759678 -
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
|
Phase 2 | |
Recruiting |
NCT01052623 -
Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)
|
Phase 4 |